Pfizer inc (PFE) Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer
Pfizer inc (NYSE: PFE) FY 2026 Other Release
Breaking News
BioNTech (BNTX) Reports Q4 Loss of EUR0.33/Share as COVID Vaccine Revenue Plunges; Founders Exit
BioNTech posts wider-than-expected Q4 loss of $0.33/share as COVID vaccine revenue plunges 24% year-over-year; founders to exit for new mRNA venture.
Pfizer inc (PFE) Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis
Pfizer inc (NYSE: PFE) FY 2026 Other Release
Pfizer inc (PFE) Sec Form 10K
Pfizer inc (NYSE: PFE) Sec Form 10K
ADVERTISEMENT
Pfizer inc (PFE) PADCEV + Keytruda Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
Pfizer inc (NYSE: PFE) FY 2026 Other Release
Pfizer inc (PFE) U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer
Pfizer inc (NYSE: PFE) FY 2026 Other Release
Pfizer inc (PFE) Pfizer Discussion at Healthcare Conference
Pfizer inc (NYSE: PFE) FY 2026 Corporate Conference
Pfizer inc (PFE) Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
Pfizer inc (NYSE: PFE) FY 2026 Other Release
ADVERTISEMENT
AlphaGraphs
Key highlights from Pfizer’s (PFE) Q4 2025 earnings results
Pfizer Inc. (NYSE: PFE) reported its fourth quarter 2025 earnings results today. Revenues dipped 1% year-over-year to $17.6 billion. On an operational basis, revenues were…
Pfizer inc (PFE) Q2 2025 Earnings Call Transcript
Pfizer inc (NYSE: PFE) Q2 2025 Earnings Call dated Aug. 05, 2025 Corporate Participants: Francesca DeMartino — Chief Investor Relations Officer, Senior Vice President Albert…